DHR trades 3.7% below Wall Street's consensus target of $238.77.
Last 12 months price action with 12-month analyst target path
The base valuation assumes DHR achieves its forward estimates and maintains a stable P/E multiple of 26.8x. This scenario reflects the blended consensus of 43 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Danaher Corporation (DHR) has a Wall Street consensus price target of $238.77, based on estimates from 43 covering analysts. With the stock currently trading at $230.25, this represents a potential upside of +3.7%. The company has a market capitalization of $161.86B.
Analyst price targets range from a low of $195.00 to a high of $275.00, representing a 34% spread in expectations. The median target of $240.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 31 analysts rating the stock as a Buy or Strong Buy,11 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, DHR trades at a trailing P/E of 45.7x and forward P/E of 26.8x. The forward PEG ratio of 44.24 reflects a premium valuation. Analysts expect EPS to grow +40.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $370.91, with bear and bull scenarios of $233.67 and $488.71 respectively. Model confidence stands at 54/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 TMOThermo Fisher Scientific Inc. | $258.2B | $694.76 | $694.27 | -0.1% | Buy | 27.5x | 43 |
 AAgilent Technologies, Inc. | $49.4B | $174.76 | $174.29 | -0.3% | Buy | 28.2x | 41 |
 WATWaters Corporation | $34.2B | $457.60 | $470.00 | +2.7% | Buy | 31.2x | 37 |
 BIOBio-Rad Laboratories, Inc. | $10.3B | $381.57 | $350.00 | -8.3% | Buy | 38.2x | 14 |
 BRKRBruker Corporation | $9.3B | $61.31 | $67.00 | +9.3% | Buy | 28.9x | 33 |
 MTDMettler-Toledo International Inc. | $34.8B | $1722.15 | $1552.00 | -9.9% | Hold | 36.4x | 19 |
 IDXXIDEXX Laboratories, Inc. | $53.3B | $676.04 | $716.67 | +6.0% | Buy | 45.5x | 23 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 IQVIQVIA Holdings Inc. | $44.7B | $271.83 | $289.91 | +6.7% | Buy | 21.0x | 45 |
 QGENQiagen N.V. | $10.4B | $50.33 | $44.14 | -12.3% | Hold | 20.7x | 30 |
Quick answers to the most common questions about buying DHR stock.
The consensus price target for DHR is $238.77, close to the current price of $230.25 (3.7% implied move). Based on 43 analyst estimates, the stock appears fairly valued near current levels.
DHR has a consensus rating of "Buy" based on 43 Wall Street analysts. The rating breakdown is predominantly bullish, with 31 Buy/Strong Buy ratings. The consensus 12-month price target of $238.77 implies 3.7% upside from current levels.
DHR trades at a forward P/E of 26.8125x, representing a moderate valuation. With analysts targeting $238.77 (3.7% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $275 for DHR, while the most conservative target is $195. The consensus of $238.77 represents the median expectation. Our quantitative valuation model projects a bull case target of $489 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
DHR is heavily covered by Wall Street, with 43 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 30 have Buy ratings, 11 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month DHR stock forecast based on 43 Wall Street analysts shows a consensus price target of $238.77, with estimates ranging from $195 (bear case) to $275 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $371, with bear/bull scenarios of $234/$489.
Our quantitative valuation model calculates DHR's fair value at $371 (base case), with a bear case of $234 and bull case of $489. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 54/100.
DHR trades at a forward P/E ratio of 26.8x based on next-twelve-months earnings estimates compared to a trailing P/E of 45.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
DHR appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $238.77 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
DHR analyst price targets range from $195 to $275, a 34% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $238.77 consensus represents the middle ground. Our model's $234-$489 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.